ELISA SALAZAR: Open Payments
NPI 1225359961 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,909 in 83 payments from 16 companies in 2025. Trend: 2023 $790 · 2024 $1,258 · 2025 $1,909
Food & beverage: $1,909
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $314 |
| Otsuka America Pharmaceutical, Inc. | 9 | $237 |
| E.R. Squibb & Sons, L.L.C. | 7 | $213 |
| Axsome Therapeutics, Inc. | 6 | $213 |
| Neurocrine BioSciences, Inc. | 3 | $177 |
| Janssen Pharmaceuticals, Inc | 4 | $174 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $142 |
| Teva Pharmaceuticals USA, Inc. | 4 | $91 |
| Corium, LLC | 5 | $75 |
| Tris Pharma Inc | 3 | $62 |
Products named: VRAYLAR, COBENFY, Auvelity, INGREZZA, SPRAVATO, CAPLYTA, ABILIFY MAINTENA, REXULTI.
Industry payments across ID — which companies pay providers there.
